Conference on 2nd Biosimilars Congregation 2013 promote a new conference on “2nd Biosimilars Congregation 2013” which discuss on Commercial challenges, opportunities and strategies to develop Biosimilars.


2nd Biosimilars Congregation 2013 To be held on 19th and 20th Feb 2013 at Marriott Hotel , London UK


According to Global Industry Analysts Inc. The global market for biosimilars is forecast to reach US$4.8 billion by the year 2015. By 2020, some $55 Billion worth of biologic patents are due to expire. Key factors driving market growth include patent expiries of key biological drugs, cost containment measures from governments, aging population, and supporting legislations. The recent establishment of regulatory guidelines for biosimilars in the US is expected to add further momentum to the growth of the global biosimilars market. Increasing pressure from governments and insurers for greater biologic competition, there exists an incredible opportunity for biosimilar producers to capitalise on what is set to become the fastest growing sector of the pharmaceutical industry.


The barriers to entry for this lucrative market however require that companies establish and harmonise carefully planned regulatory, clinical and marketing strategies. Innovators and biosimilar applicants need to find answers to the current myriad of commercialisation questions that face the market. Those to establish their market presence first will dictate the success of companies in the biosimilar space.


Europe holds the highest number of biosimilar approvals, and this number will continue to increase in the near future. Further biologic patent expiries will boost the number of biosimilars to be approved, thereby bringing in an increased number of products that will help increase market size and competition among market participants. The biosimilars market is in the nascent stage of the industry life cycle with limited market and product development experience. However, there is a significant market opportunity from patent expiries. High initial investments are still a major barrier for new entrants. Collaborations among large pharmaceutical companies with financial capabilities and specialty biotech companies with technical expertise are expected. The strong integration of marketing and research and development skills is the key to success in the biosimilars market.


The Conference will bring together top pharmaceutical, biotechnology and regulatory representatives under one roof that will address the key issues of the industry. Hence, this 3rd Biosimilars Congregation 2013 will look at the multiple facets of biosimilars, ranging from the evolving regulatory landscape and challenges in clinical development, to the legal and economic aspects. By attending this conference you will gain a comprehensive outlook on the key issues surrounding biosimilars. This event will provide an important platform for Biosimilars stakeholders to discuss and share best practices in expediting Biosimilars development.


 Key Speakers Include:-

 Paul Tredwell, Head of Biopharmaceuticals, Sandoz

 Anne Cook, Biologicals Quality Assessor, MHRA

 Cecil Nick, Vice President, Biotechnology, Parexel

 Yariv Hefez, Vice President Business Development & Alliance Management, Biosimilars, Merck Serono

 Alex Kudrin, Medical Assessor in Licensing of Biological Products, MHRA (Former Medical Director,Takeda Pharmaceuticals )

 Malcolm I Mitchell, Senior Medical Fellow, Clinical Pharmacology, Eli Lilly


 For more information kindly visit :                         




 Contact us at :


 Company Profiles And Conferences

 Phone: +91 22 27810772, 27810773

 Fax: +91 22 27810778

 Email : [email protected]

 Website :

 Our Blogs :